Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SeaStar Medical Holding Corp

Get SEC filing alerts via email and in your feed for SeaStar Medical Holding Corp

ICU ICUCW

SeaStar Medical Holding Corp

About SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation develops extracorporeal medical devices targeting hyperinflammation and organ failure. Its flagship product, the Selective Cytopheretic Device (SCD), modulates immune cells to treat acute and chronic inflammatory conditions, including acute kidney injury, cardiorenal syndrome, and liver failure. The company focuses on regulatory approval, clinical trials, and strategic partnerships to commercialize its innovative, organ-agnostic therapy for critically ill patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SeaStar Medical Holding Corp

1
1
SeaStar Medical Holding Corp SeaStar Medical Reports 69% Revenue Growth to $495,000 in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
SeaStar Medical Holding Corp SeaStar Medical Reports $1.2 Million Revenue Growth and $12.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
SeaStar Medical Holding Corp SeaStar Medical Reports Revenue Growth and Reduced Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SeaStar Medical Holding Corp SeaStar Medical Reports $338,000 Revenue in Q2 2025, Sees Improvement in Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SeaStar Medical Holding Corp SeaStar Medical Reports $293,000 Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SeaStar Medical Holding Corp SeaStar Medical Reports $24.8 Million Net Loss, First Revenue from QUELIMMUNE Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SeaStar Medical Holding Corp SeaStar Medical Reports Revenue Growth, Improved Financial Position, and Challenges Ahead

Via official filing (AI summary) | over 1 year ago | 0 comments